Complement-Coagulation Cross-talk: Factor H-mediated regulation of the Complement Classical Pathway activation by fibrin clots.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 11 01 2024
accepted: 06 05 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

The classical pathway of the complement system is activated by the binding of C1q in the C1 complex to the target activator, including immune complexes. Factor H is regarded as the key downregulatory protein of the complement alternative pathway. However, both C1q and factor H bind to target surfaces via charge distribution patterns. For a few targets, C1q and factor H compete for binding to common or overlapping sites. Factor H, therefore, can effectively regulate the classical pathway activation through such targets, in addition to its previously characterized role in the alternative pathway. Both C1q and factor H are known to recognize foreign or altered-self materials, e.g., bacteria, viruses, and apoptotic/necrotic cells. Clots, formed by the coagulation system, are an example of altered self. Factor H is present abundantly in platelets and is a well-known substrate for FXIIIa. Here, we investigated whether clots activate the complement classical pathway and whether this is regulated by factor H. We show here that both C1q and factor H bind to the fibrin formed in microtiter plates and the fibrin clots formed under

Identifiants

pubmed: 38933264
doi: 10.3389/fimmu.2024.1368852
pmc: PMC11199686
doi:

Substances chimiques

Complement Factor H 80295-65-4
Fibrin 9001-31-4
Complement C1q 80295-33-6
CFH protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1368852

Informations de copyright

Copyright © 2024 Kang, Varghese, Aiyan, Pondman, Kishore and Sim.

Déclaration de conflit d'intérêts

Author Y-HK was employed by the company MediMabBio Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Yu-Hoi Kang (YH)

Medical Research Council Immunochemistry Unit, Department of Biochemistry, University of Oxford, Oxford, United Kingdom.
MediMabBio Inc., Pangyo Business Growth Centre, Gyeonggi-do, Republic of Korea.

Praveen M Varghese (PM)

School of Biosciences and Technology, Vellore Institute of Technology, Vellore, India.

Ahmad Al Aiyan (AA)

Department of Veterinary Medicine (CAVM), United Arab Emirates University, Al Ain, United Arab Emirates.

Kirsten Pondman (K)

Applied Microfluidics for BioEngineering Research, MESA+ Institute for Nanotechnology & TechMed Centre, University of Twente, Enschede, Netherlands.

Uday Kishore (U)

Department of Veterinary Medicine (CAVM), United Arab Emirates University, Al Ain, United Arab Emirates.
Zayed Centre for Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.

Robert B Sim (RB)

Medical Research Council Immunochemistry Unit, Department of Biochemistry, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH